Mainz

• A study to evaluate the effect of venglustat tablets on neuropathic and abdominal pain in male and female participants ≥16 years of age with … Ended recruitment
  2024-511990-31-00 5 2022-06-28 Fabry Disease
• A Randomised, Open-Label, Phase 2 Study of Ceralasertib Monotherapy and Ceralasertib plus Durvalumab in Patients with Unresectable or Advanc … Ended recruitment
  2024-512378-91-00 4 2022-06-24 Unresectable or Advanced Melanoma
• A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus (EMERALD) Ended recruitment
  2023-505635-13-00 5 2022-06-10 Systemic lupus erythematosus
• A study to investigate the short- and long-term safety and tolerability of the drug SNDX-5613 in Patients with Relapsed/Refractory Leukemias … Ended recruitment
  2024-513759-34-00 7 2022-05-31 Relapsed or Refractory Acute Leukemias
• IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio … Ended recruitment
  2023-506854-19-00 1 2022-05-19 Solid Tumors
• A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myel … Ended recruitment
  2023-507469-24-00 4 2022-04-30 Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodyspl
• A Phase 3 Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Ended recruitment
  2023-508897-27-00 5 2022-04-28 Multiple Myeloma
• A study in patients with skin cancer Ended recruitment
  2024-516914-39-00 5 2022-04-27 Metastatic or unresectable melanoma
• Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritis Ended recruitment
  2023-506359-68-00 5 2022-04-08 Active Proliferative Lupus Nephritis
• Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis Ended recruitment
  2023-504597-37-00 5 2022-03-25 Focal segmental glomerulosclerosis
• A Study to Evaluate the Efficacy and Safety of BIIB059 in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background N … Ended recruitment
  2023-505696-74-00 5 2022-02-10 systemic lupus erythematosus
• A Phase II, single-arm trial of Atezolizumab/Platinum/Etoposide for the treatment of advanced large-cell neuroendocrine cancer of the lung ( … Ended recruitment
  2024-515902-15-00 4 2022-01-18 Male and female adult patients with locally advanced or metastatic lar
• A study to investigate the efficacy and safety of trastuzumab deruxtecan as the first treatment option for locally advanced/metastatic Non-S … Ended recruitment
  2023-503674-20-00 5 2021-12-17 Unresectable, locally advanced, or metastatic Non-Small Cell Lung Canc
• A clinical study to assess the efficacy and safety of lanifibranor followed by an active treatment extension in adult patients with non-cirr … Ended recruitment
  2023-508248-23-00 5 2021-11-26 Non-alcoholic steatohepatitis (NASH)
• Additional chemotherapy for EGFRm patients with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib 1st-line t … Ended recruitment
  2024-517965-18-00 4 2021-11-11 Advanced NSCLC with common EGFR-Mutation
• Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati … Ended recruitment
  2023-507342-84-00 5 2021-10-26 Bladder Cancer
• ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease … Ended recruitment
  2023-506926-35-00 5 2021-09-24 Atherosclerotic cardiovascular disease, chronic kidney disease and sys
• A rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with prim … Ended recruitment
  2023-508690-92-00 11 2021-09-20 IgA Nephropathy
• A study to learn if dapirolizumab pegol is safe and works long-term in people with systemic lupus erythematosus Ended recruitment
  2023-506368-14-00 5 2021-09-07 Systemic lupus erythematosus (SLE)
• A Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel versus Bortezomib, Len … Ended recruitment
  2023-505850-16-00 5 2021-08-05 Multiple Myeloma
• Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla … Ended recruitment
  2024-516096-32-00 4 2021-08-05 Platinum sensitive recurrent ovarian cancer
• PEITHO-3 - A reduced dose of thrombolytic treatment for patients with intermediate high-risk acute pulmonary embolism: a randomized controll … Ended recruitment
  2024-511321-54-00 5 2021-08-04 intermediate-high-risk acute pulmonary embolism
• Trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to standard therapy versus standard therapy in patients … Ended recruitment
  2022-500237-92-00 5 2021-04-23 Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
• Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f … Ended recruitment
  2023-507961-24-00 5 2021-04-19 High-Risk HER2-Positive Breast Cancer

Showing 361–384 of 589 trials